We do not support your browser. Please take a moment and upgrade to the most recent version of Internet Explorer.
CTSI Directory

William Boyle, Ph.D. [ Edit Your Profile ]

Email Address: wboyle@mednet.ucla.edu

UC Braid Co-Leader Therapeutics, CAI
UCLA Associate Professor, Pulmonary and Critical Care Medicine



Dr. Boyle is an Associate Professor in the Department of Medicine in the David Geffen School of Medicine. Dr. Boyle leads an important consultation service for CTSI DGSOM faculty related to the discoveries-to-products pipeline. He also has a leading role in the DGSOM Accelerator to identify emerging technologies and drug concepts to help drive the value generation of university assets that will bring in revenues to help fund internal programs and other initiatives. As a senior executive with over 20 years of experience in the pharmaceutical and biotechnology industry, he is highly qualified for this role. Dr. Boyle has extensive experience in translational medicine, project management, target selection, pipeline management, and platform translation. Dr. Boyle received his doctorate degree in Experimental Pathology from the UCLA School of Medicine and subsequently completed a postdoctoral fellowship in Molecular Biology and Virology at the Salk Institute. He began his research career at Amgen in 1990, where he was involved in the discovery and development of novel protein and small molecule candidate therapeutics for over eleven years. His research in discovery and development within the immunology/inflammation, oncology, and bone therapeutic areas has been published extensively in peer-reviewed journals.

Lacey David L, Boyle William J, Simonet W Scott, Kostenuik Paul J, Dougall William C, Sullivan John K, San Martin Javier, Dansey Roger, Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nature reviews. Drug discovery. 2012; 11(5): 401-19.
Bowers Peter M, Horlick Robert A, Neben Tamlyn Y, Toobian Rachelle M, Tomlinson Geoffrey L, Dalton Jennifer L, Jones Heather A, Chen Andy, Altobell Laurence, Zhang Xue, Macomber John L, Krapf Irina P, Wu Betty F, McConnell Audrey, Chau Betty, Holland Trevin, Berkebile Ashley D, Neben Steven S, Boyle William J, King David J, Coupling mammalian cell surface display with somatic hypermutation for the discovery and maturation of human antibodies. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108(51): 20455-60.
Bornstein Gadi Gazit, Klakamp Scott L, Andrews Laura, Boyle William J, Tabrizi Mohammad, Surrogate approaches in development of monoclonal antibodies. Drug discovery today. 2009; 14(23-24): 1159-65.
Kostenuik Paul J, Nguyen Hung Q, McCabe James, Warmington Kelly S, Kurahara Carol, Sun Ning, Chen Ching, Li Luke, Cattley Russ C, Van Gwyneth, Scully Shelia, Elliott Robin, Grisanti Mario, Morony Sean, Tan Hong Lin, Asuncion Frank, Li Xiaodong, Ominsky Michael S, Stolina Marina, Dwyer Denise, Dougall William C, Hawkins Nessa, Boyle William J, Simonet William S, Sullivan John K, Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2009; 24(2): 182-95.
Kwak Keith S, Zhou Xiaolan, Solomon Vered, Baracos Vickie E, Davis James, Bannon Anthony W, Boyle William J, Lacey David L, Han H Q, Regulation of protein catabolism by muscle-specific and cytokine-inducible ubiquitin ligase E3alpha-II during cancer cachexia. Cancer research. 2004; 64(22): 8193-8.
Boyle William J, Simonet W Scott, Lacey David L, Osteoclast differentiation and activation. Nature. 2003; 423(6937): 337-42.
Eghbali-Fatourechi Guitty, Khosla Sundeep, Sanyal Arunik, Boyle William J, Lacey David L, Riggs B Lawrence, Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. The Journal of clinical investigation. 2003; 111(8): 1221-30.
Bolon Brad, Shalhoub Victoria, Kostenuik Paul J, Campagnuolo Giuseppe, Morony Sean, Boyle William J, Zack Debra, Feige Ulrich, Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis. Arthritis and rheumatism. 2002; 46(12): 3121-35.
Theill Lars E, Boyle William J, Penninger Josef M, RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annual review of immunology. 2002; 20(12): 795-823.
Shalhoub V, Elliott G, Chiu L, Manoukian R, Kelley M, Hawkins N, Davy E, Shimamoto G, Beck J, Kaufman S A, Van G, Scully S, Qi M, Grisanti M, Dunstan C, Boyle W J, Lacey D L, Characterization of osteoclast precursors in human blood. British journal of haematology. 2000; 111(2): 501-12.
Lacey D L, Tan H L, Lu J, Kaufman S, Van G, Qiu W, Rattan A, Scully S, Fletcher F, Juan T, Kelley M, Burgess T L, Boyle W J, Polverino A J, Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. The American journal of pathology. 2000; 157(2): 435-48.
Min H, Morony S, Sarosi I, Dunstan C R, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik P J, Lacey D L, Boyle W J, Simonet W S, Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. The Journal of experimental medicine. 2000; 192(4): 463-74.

Cite the Grant Number Trial Innovation Network Smart IRB